"Now I’ve got to the point where I think we can get almost complete control of cardiovascular disease, heart attacks and strokes by the proper use of vitamin C and lysine. It can prevent cardiovascular disease and even cure it." Linus Pauling Interview, Journal of Orthomolecular Medicine, 1994.
Still Have Questions About the Pauling Therapy?
"Every person in America — every person in the world — should be made aware of this discovery. We cannot imagine a valid reason for performing another coronary artery bypass graft surgery, angioplasty, or stent placement . . . without first trying Pauling’s therapy."
~Owen Fonorow, Sally
Medicine Without a License? The Story of the Linus Pauling Therapy for Heart Disease © 2008
The Missing Enzyme
According to Linus Pauling and others, the condition that doctors euphemistically label as "coronary heart disease" is not a disease at all. Rather, it is a symptom of an enzyme missing in humans that is needed in order to make ascorbic acid (vitamin C) in the body - the enzyme gulonolactone oxidase, or GLO. Because humans cannot make vitamin C in the liver like most animals, they require high levels of ascorbic acid in the diet in order to manufacture the vast amounts of collagen required for the maintenance of blood vessels, bones, organs, skin, ligaments, cartilage, and teeth. The coronary arteries typically suffer the scorbutic (scurvy) effect from the lack of vitamin C and collagen and begin to deterioriate first because they are subject to the greatest degree of mechanical stress from the pumping action of the beating heart. However, the deficiency is global, ocurring throughout the body.
Plaque forms on a coronary artery to patch it when the artery is deficient in collagen from a chronic ascorbic acid (vitamin C) deficiency, a condition known as scurvy.
Arterial scurvy is reversed only with intake of the levels of vitamin C recommended by Pauling to make collagen, while the reinforcing plaque is attracted to and eliminated by the amino acid components of Pauling's therapy, a/k/a Lp(a) binding inhibitors.
News That Should Have Changed the World
Pauling himself indicated during a 1994 Interview when questioned about the significance of these findings:
THE PAULING THERAPY
IS IT A "CURE" FOR HEART DISEASE?
Disclaimer: The Food and Drug Administration (FDA) has not evaluated any statements on this Website. Tower Laboratories Corporation does not make health claims for its products. Tower Laboratories products are not intended to diagnose, treat or cure any disease. Tower is not responsible for independent third parties who may otherwise represent the efficacy of its products. These individuals are not Tower's agents and do not have permission to do so. Unsatisfactory products sold in the USA may be returned for a full refund within 60 days of the original ship date.
In Pauling's last private telephone interview with reporter Peter Barry Chowka conducted on April 9, 1994, he expressed his dismay that this theory of heart disease wasn't formulated and the disease eradicated decades earlier, stating:
". . . I have trouble understanding why somebody interested in heart disease didn't think of it 20 or 30 years ago when it was accepted by cardiologists that the primary cause of atherosclerosis and heart disease is a lesion in the wall of an artery in a region of stress. So I asked myself two or three years ago, 'Why should there be a lesion in the wall of the artery?' Animals don't have these lesions in regions of stress. Well, you have the lesions because arteries are weak. Why are they weak? Ordinarily, animals' arteries are strengthened by the deposit of collagen. And you can't make collagen without using up vitamin C. Humans don't get enough vitamin C, so their arteries are weak. And then a lesion forms, followed by the other stages of developing heart disease. THEREFORE, DEFICIENT INTAKE OF VITAMIN C IS A PRIMARY CAUSE OF CARDIOVASCULAR DISEASE."
Tower products are not a frank "cure" because they do not replace the body's missing enzyme (the true disease). Rather, Tower products replace the nutrient - vitamin C - that other species WITH the enzyme are able to make that prevents them from suffering from coronary heart disease.
LEARN MORE ABOUT VITAMIN C AND HEART DISEASE IN OUR BOOKS AND DVD, AVAILABLE FOR PURCHASE NOW.
The Problem - U. S. RDA Causes Arterial Scurvy
The miniscule amount of vitamin C in the U. S. RDA of 60 to 75 mg will prevent death from the vitamin C deficiency disease scurvy but is not nearly sufficient for the body to make enough collagen to maintain the strength and integrity of its entire cardiovascular system as well as bones, cartilage, organs, etc. The amount of daily vitamin C necessary to treat latent or chronic scurvy, also known as human atherosclerosis, is nearly 100 times higher than the RDA. No human who consumes the RDA of 75 mg or less is immune to coronary heart and cardiovascular disease. In fact, Pauling's research concluded that daily intake of no less than 3,000 mg is required for adequate collagen synthesis and protection from heart disease, and that daily intake of no less than 6,000 mg is required for those with diagnosed heart disease.
The Discovery - Lipoprotein (a) Cholesterol
Lipoprotein (a) (Lp(a)), discovered in 1963, is a low-density lipoprotein cholesterol particle whose presence in the blood represents a high risk factor for coronary heart disease, cerebrovascular disease, atherosclerosis, thrombosis and stroke. Unfortunately, testing for Lp(a) is not typically performed during routine cholesterol testing and thus, most people are unaware of their true heart disease risk. The results of a large U.S. study, published in The New England Journal of Medicine in 2003, suggest that among older adults in the United States, elevated Lp(a) lipoprotein is an independent predictor of stroke, death from vascular disease, and death from any cause, especially in men. These data support the use of Lp(a) lipoprotein level testing in predicting the risk of these events. See Lp(a) Lipoprotein, Vascular Disease, and Mortality in the Elderly. See Also Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent Advances and Future Directions.
The Invention - Lipoprotein (a) Binding Inhibitors
In 1987 Lipoprotein(a) - Lp(a) - cholesterol molecules were found to contain "lysine binding sites" that are responsible for the deposit of plaques on the walls of arteries when they are deficient in collagen, which results from too little vitamin C intake (arterial scurvy). Arteries deficient in collagen deterioriate and their walls become weak. Plaques are the body's way of "patching" these failing arteries to prevent them from rupturing. This occurs because of something called the "lysine binding site" on the Lp(a) molecules circulating in the blood. When this damage occurs to the tissue of the artery wall, it exposes the amino acid lysine within the tissue. Because Lp(a) has a natural attraction to lysine, it sticks to the lysine in the damaged artery walls and creates a natural plaster "cast" that shores up the arteries. Without this repair mechanism the arteries would rupture or leak blood and cause death from this chronic form of scurvy much sooner.
Based on this finding, Linus Pauling and his associate Matthias Rath formulated in 1989 A Unified Theory of Human Cardiovascular Disease which was published in the Journal of Orthomolecular Medicine in 1992 and invented what Tower has coined as the "Pauling therapy" (vitamin C/lysine and other nutrients) treatment for heart disease. Vitamin C and lysine in large amounts (and smaller amounts of proline and other nutrients) become Lp(a) cholesterol binding inhibitors that restore vascular health and are patented to release atherosclerotic plaques. Pauling's experiments proved that "simply administering the proper nutrients, in the proper combination, at the proper dosage could eradicate heart disease." NOTE: Most Pauling therapy users report elevations in cholesterol in the months after beginning the Pauling therapy, which indicates clearly that Pauling was correct and the proper combination of C and lysine will cause a release of fatty plaques from the blood vessels. In time (6-9 months depending on the amount of fatty plaque that must be released and cleared from the body by the liver) blood cholesterol levels begin to fall, as evidenced by William Cook's testimonial of his own experience with this phenomenon.
16 Years of Proof
Tower's experience since 1996 demonstrates that replacement dosages of ascorbic acid (vitamin C), lysine and the other nutrients in the amounts recommended by Linus Pauling rapidly reverse the symptoms of heart disease in most people including angina, atherosclerosis, high blood pressure and high cholesterol, and thereby lower the risk of heart attack and stroke.
The science behind Tower's products and the effectiveness of the Pauling therapy are explained and corroborated by 17 years of positive customer testimonials and are now documented in the following resources:
Know Your Own Lp(a) Score!
The Lipoprotein (a) test is seldom ordered by physicians in routine cholesterol testing, and most continue to remain ignorant about the importance of this test. Nearly half of all people who suffer heart attacks have normal cholesterol panels but elevated Lp(a). You can obtain your own Lp(a) measurement by asking your doctor to order an Lp(a) test at your next office visit. This is especially important for those with a family history of elevated Lp(a) levels and/or a family history of premature CAD; or if you have heart disease but your lipid profile is normal or shows only mildly elevated levels of cholesterol and/or low-density lipoprotein cholesterol (LDL-C).
Be sure to ask the testing facility whether your Lp(a) score will be measured (true value) or computed (estimated value). If the test is not available through your doctor or if he knows conclusively that the laboratory performing the test simply computes Lp(a) values, you can also ask your doctor to order a VAP Cholesterol Test from Atherotech, which is a very reliable lipoprotein (a) test for determining true heart attack risk.
Made in the U.S.A. • Copyright © 2008 • All Rights Reserved.
Tower Laboratories Corporation • 5575 Simmons Street, Ste 1, #253 • North Las Vegas, NV 89031 •